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OBJECTIVE—Factors governing microRNA expressions in re-
sponse to changes of cellular environment are still largely
unknown. Our aim was to determine whether insulin, the major
hormone controlling whole-body energy homeostasis, is involved
in the regulation of microRNA expressions in human skeletal
muscle.
RESEARCH DESIGN AND METHODS—We carried out com-
parative microRNA (miRNA) expression proﬁles in human skel-
etal muscle biopsies before and after a 3-h euglycemic-
hyperinsulinemic clamp, with TaqMan low-density arrays. Then,
using DNA microarrays, we determined the response to insulin of
the miRNA putative target genes in order to determine their role
in the transcriptional action of insulin. We further characterized
the mechanism of action of insulin on two representative
miRNAs, miR-1 and miR-133a, in human muscle cells.
RESULTS—Insulin downregulated the expressions of 39 dis-
tinct miRNAs in human skeletal muscle. Their potential target
mRNAs coded for proteins that were mainly involved in insulin
signaling and ubiquitination-mediated proteolysis. Bioinformatic
analysis suggested that combinations of different downregulated
miRNAs worked in concert to regulate gene expressions in re-
sponse to insulin. We further demonstrated that sterol regulatory
element–binding protein (SREBP)-1c and myocyte enhancer factor
2C were involved in the effect of insulin on miR-1 and miR-133a
expression. Interestingly, we found an impaired regulation of
miRNAs by insulin in the skeletal muscle of type 2 diabetic patients,
likely as consequences of altered SREBP-1c activation.
CONCLUSIONS—This work demonstrates a new role of insulin
in the regulation of miRNAs in human skeletal muscle and
suggests a possible implication of these new modulators in
insulin resistance. Diabetes 58:2555–2564, 2009
I
nsulin is one of the major hormones involved in the
control of energy expenditure and carbohydrate,
lipid, and protein metabolism. It also regulates a
variety of biological processes such as protein turn-
over, cell growth and differentiation, and DNA synthesis.
To perform these actions in a concerted manner, insulin
coordinates a complex program of transcriptional changes
(1,2) in the human skeletal muscle.
Recently, our understanding of complex gene regulatory
networks governing cell physiology has rapidly evolved
with the discovery of microRNAs (miRNAs). They repre-
sent a large class of evolutionary conserved RNAs of 21–22
nt, which act as negative regulators of gene expression
either by inhibiting mRNA translation or promoting mRNA
degradation through base pairing to the 3 untranslated
region (UTR) of target mRNAs (3). These small noncoding
RNAs are transcribed by RNA polymerase II–producing
long primary transcripts (pri-miRNAs), which are then
processed by Drosha and Pasha (also DGCR8), which
result in a stem-loop precursor called premiRNA. The
pre-miRNA is subsequently transported from the nucleus
to the cytoplasm by exportin-5 (XPO5). Then, DICER1
(RNase III endonuclease) processes the stem-loop to
produce a 21-bp RNA duplex. One strand of the duplex, the
miRNA, enters the RNA-induced silencing complex (RISC)
and directs the complex to target mRNA (4). In agreement
with their important regulatory functions, global effects of
miRNAs upon the transcriptional proﬁle and tissue speci-
ﬁcity of mRNA expression have been reported in response
to experimental manipulations of miRNA levels (5–7), and
the latest estimate indicates that they may regulate up to
one-third of the mammalian genome (8).
Important roles for these miRNAs have emerged in the
control of metabolic pathways, as suggested by studies
implicating miRNAs in the regulation of fat metabolism,
adipocyte differentiation, energy homeostasis, and glu-
cose-stimulated insulin secretion (9).
Skeletal muscle is one of the largest tissues in the
human body and is the major site for insulin-dependent
glucose disposal. Changes in mRNA and protein abun-
dance in this tissue are central to a large number of
metabolic and other disorders, including insulin resis-
tance. The discovery that some miRNAs are expressed
speciﬁcally in skeletal muscle raises the question of their
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insulin in this tissue (10). Here, we report that insulin
regulates miRNA expressions in the human skeletal mus-
cle in vivo, which in return participate in insulin transcrip-
tional action in this tissue. We also demonstrated that
miR-1 and miR-133a, speciﬁcally expressed in muscle
tissues (11–13), are regulated by insulin via sterol regula-
tory element–binding protein (SREBP)-1c and myocyte
enhancer factor 2C (MEF2C). Furthermore, we found that
miR-1 and miR-133a have impaired insulin response in the
skeletal muscle of type 2 diabetic patients.
RESEARCH DESIGN AND METHODS
Euglycemic-hyperinsulinemic clamps. Volunteers provided written con-
sent, and protocols were approved by an ethics committee (Hospices Civils,
Lyon, France). Fifteen subjects without history of diabetes were submitted to
a 3-h euglycemic-hyperinsulinemic clamp to achieve supraphysiological
plasma insulin concentrations (insulin infusion rate of 2 mU  min
1 kg
1).
Five subjects among 15 were selected based on their ages (51  2 years). Their
response to insulin infusion was compared with the response of ﬁve insulin-
resistant type 2 diabetic patients (aged 50  3 years) who had interrupted
their usual treatment with oral antidiabetes agents at least 5 days before
investigations. Metabolic parameters are presented in the online appendix in
Table S1 (available at http://diabetes.diabetesjournals.org/cgi/content/full/
db09-0165/DC1). Percutaneous biopsies of the vastus lateralis muscle were
performed under basal conditions and after the clamp study.
Hyperglycemic-euinsulinemic clamp. Seven healthy men were submitted to
a 3-h hyperglycemic-euinsulinemic clamp with infusion of somatostatin to
inhibit endogenous insulin release. Muscle biopsies of vastus lateralis muscles
were performed under basal conditions and after the clamp study as described
previously (14).
Streptozotocin-induced diabetic mice. Three groups of 10-week-old
C57Bl/6 males were used (n  6). The control group was given daily
intraperitoneal injections of sodium citrate buffer for 3 days. The remaining
two groups were made diabetic by daily intraperitoneal injection of strepto-
zotocin (STZ) for 3 consecutive days. Glucose levels were monitored daily,
and mice were studied when they achieved fed blood sugars 500 mg/dl for
at least 3 days. One group was further treated with two injections of insulin (3
mU Insulatard; Novo Nordisk). Twenty-four hours after the ﬁrst injection of
insulin, all animals were killed and gastrocnemius muscles were removed.
miRNA expression proﬁles in human muscle cells or skeletal muscle
biospsies. Differentiated myotubes were prepared from three different skel-
etal muscle biopsies from three healthy volunteers (15). We quantiﬁed the
expression of 365 human miRNAs in myoblasts in and differentiated myo-
tubes, or in skeletal muscle biospies, by using the TaqMan low-density arrays
with the Applied Biosystems 7900HT fast real-time PCR system.
Quantiﬁcation of mature miRNAs. Mature human or mouse miRNA ex-
pressions were quantiﬁed by using the TaqMan miRNA assays according to the
manufacturer’s instructions. To account for possible differences in the amount
of starting RNA, all samples were normalized to RNU48.
Quantitative real-time PCR. Primers are given in supplementary Table S2.
Quantitative RT-PCR data were computed as fold using geometric means and
normalized to the mean value of the control sample in each paradigm, deﬁned
as one. All experiments were performed in triplicate, and comparisons were
analyzed using Student’s t test. Data are expressed as means  SE. Signiﬁ-
cance was deﬁned as P  0.05.
Microarray analysis. cDNA microarrays are from The Stanford Functional
Genomics Facility (http://www.microarray.org/sfgf/). The dataset is available
from GEO database (GSE 11868). The 6 insulin-sensitive subjects used for
microarray analysis were included in the group of 15 (supplementary Table
S1). Signal intensities were log transformed, and normalization was performed
by Lowess method. Only spots with recorded data on the six slides were
selected for analysis. With these criteria, 26,108 spots were retrieved. Among
them, 11,864 had a gene symbol and were considered in this study as the list
of genes expressed in human muscle. Genes with fold changes 1.19 were
considered as signiﬁcantly regulated (i.e., corresponding to the 95th percentile
of genes based on the magnitude of the fold changes), which represented
1,681 genes (944 upregulated and 737 downregulated). Correction for multiple
testing was performed using the Benjamini and Hochberg procedure.
Modulation of SREBP-1c mRNA levels in primary cultures of human
muscle cells. Differentiated myotubes were infected for 48 h with adenovi-
ruses expressing either green ﬂuorescent protein (control) or nuclear SREBP-
1c, as described previously (15). To knockdown SREBP-1, differentiated
human myotubes were transfected with siRNA against SREBP-1 (Qiagen) for
36 h. Then, they were treated with 100 nmol/l insulin (Sigma Aldrich) for 5 h.
Chromatin immunoprecipitation. Differentiated C2C12 cell lines were
infected for 48 h with recombinant adenoviruses. Protein-DNA complexes
were ﬁxed for 5 min with 1% formaldehyde and proceed according to Active
Motif’s ChIP-IT Express Kit (Active Motif Europe) with MEF2C antibodies
(E-17, sc-13266; Santa Cruz).
RESULTS
miRNAs are regulated by insulin in human skeletal
muscle. To identify miRNAs regulated by insulin in human
skeletal muscle, we carried out comparative miRNA ex-
pression proﬁling in biopsies from healthy subjects, before
and after a 3-h euglycemic-hyperinsulinemic clamp, by
using TaqMan low-density arrays combined with multiplex
RT-PCR to quantify 365 mature human miRNAs from the
miRBase database (16). A subset of 216 human miRNAs
was found to be expressed in skeletal muscle biopsies
(Fig. 1). Since miRNAs are expressed in a tissue-speciﬁc
manner (10), we identiﬁed those speciﬁcally expressed in
human muscle by using primary cultures of myoblasts and
in vitro–differentiated myotubes prepared from human
skeletal muscle biopsies. Among 216 miRNAs expressed in
skeletal muscle, 192 were expressed in myoblasts and/or
myotubes, conﬁrming their presence in muscle cells (Fig.
1 and supplementary Table S3). Among them, 39 were
found downregulated by insulin in skeletal muscle of
healthy subjects (none were upregulated) (Fig. 1 and
Table 1). They represent two different classes of miRNAs;
39% are synthesized from primary transcripts located in
the noncoding regions (i.e., intergenic miRNAs) and 61%
are expressed from introns of protein-coding transcripts
(i.e., intronic miRNAs). Although they have two different
modes of transcription (17,18), their coordinated down-
regulation during hyperinsulinemia indicated that they
could share common features for regulation in response to
insulin. Of note, seven other miRNAs were also regulated
FIG. 1. Determination of miRNAs speciﬁcally expressed in muscle cells
and regulated by insulin.
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not detected in muscle cells, we assumed that they arose
from other cell types. The subset of miRNAs downregu-
lated by insulin included muscle-speciﬁc miRNAs (i.e.,
miR-1, miR-133a, and miR-206) but also miRNAs broadly
expressed in other tissues including insulin-sensitive tis-
sues (i.e., adipose tissue and liver) (10).
To further characterize the mechanism involved in the
downregulation of these miRNAs by insulin, we investi-
gated the effects of insulin on the expression of key
components of the miRNA synthesis machinery. We found
a signiﬁcant upregulation of the nuclear protein DROSHA
mRNA (P  0.01) and the cytoplasmic protein DICER1
(P  0.05) (Fig. 2), whereas expressions of DGCR8 and
XPO5 were unchanged. Regarding the expression of the
Argonaute proteins, components of the RISC complex,
mRNA levels of all except one (EIF2C1) were signiﬁcantly
increased by insulin. Together, these data indicated that
insulin positively modulated a number of speciﬁc actors of
the miRNA synthesis machinery.
Insulin regulates miR-1 and miR-133a at the tran-
scriptional level. As we found that insulin induced a
downregulation of 39 miRNAs, while at the same time
expressions of genes involved in miRNA synthesis were
upregulated, we postulated that insulin might directly
affect miRNA levels either by regulating pri-miR transcrip-
TABLE 1
miRNAs, expressed in human muscle cells, regulated in vivo by insulin in human skeletal muscle, during a 3-h hyperinsulinemic-
euglycemic clamp
miRNA names
(miRBase
version 9)
new miRNA
names* Subject 1 Subject 2 Subject 3 Means  SE Host genes Genome context
hsa-miR-95 0.75 0.81 0.6 0.72  0.06 ABLIM2 Intron Sense
hsa-miR-324-3p 0.54 0.61 0.91 0.69  0.11 ACADVL Intron Antisens
hsa-miR-324-5p 0.19 0.44 0.41 0.35  0.08 ACADVL Intron Antisens
hsa-miR-24 0.64 0.91 0.68 0.74  0.08 C9orf3 (24-1) and
intergenic (24-2)
Intron Sense
hsa-miR-27b 0.28 0.69 0.55 0.51  0.12 C9orf3 Intron Sense
hsa-miR-30a-3p hsa-miR-30a* 0.83 0.84 0.64 0.77  0.07 C6orf155 Intron Sense
hsa-miR-30a-5p 0.32 0.62 0.65 0.53  0.11 C6orf155 Intron Sense
hsa-miR-30c 0.6 0.84 0.66 0.7  0.07 NFYC (30c-1) and
C6orf155 (30c-2)
Introns Sense
hsa-miR-423 hsa-miR-423-3p 0.62 0.84 0.78 0.75  0.07 CCDC55 Intron Sense
hsa-miR-532 hsa-miR-532-5p 0.66 0.91 0.8 0.79  0.07 CLCN5 Intron Sense
hsa-miR-660 0.5 0.49 0.83 0.61  0.11 CLCN5 Intron Sense
hsa-miR-152 0.5 0.68 0.7 0.63  0.06 COPZ2 Intron Sense
hsa-miR-26b 0.6 0.74 0.94 0.76  0.1 CTDSP1 Intron Sense
hsa-miR-26a 0.52 0.78 0.89 0.73  0.11 CTDSPL (26a-1) and
CTDSP2 (26a-2)
Introns Sense
hsa-miR-616 hsa-miR-616* 0.34 0.8 0.73 0.62  0.14 DDIT3 Intron Sense
hsa-miR-126 0.56 0.93 0.86 0.78  0.11 EGFL7 Intron Sense
hsa-miR-330 hsa-miR-330-3p 0.92 0.51 0.82 0.75  0.12 EML2 Intron Sense
hsa-miR-181b 0.59 0.89 0.96 0.81  0.11 novel transcripts Introns Sense
hsa-miR-615 hsa-miR-615-3p 0.18 0.77 0.82 0.59  0.21 HOXC4 Intron Sense
hsa-miR-491 hsa-miR-491-5p 0.37 0.85 0.96 0.73  0.18 KIAA1797 Intron Sense
hsa-miR-1 0.59 0.89 0.53 0.67  0.11 MIB1 (1-2) and
C20orf166 (1-1)
Introns Sense or
antisens
hsa-miR-133a 0.27 0.75 0.59 0.54  0.14 MIB1 (133a-1) and
C20orf166
(133a-2)
Introns Sense or
antisens
hsa-miR-30e-3p hsa-miR-30e* 0.73 0.81 0.58 0.71  0.07 NFYC Intron Sense
hsa-miR-107 0.49 0.7 0.77 0.65  0.08 PANK1 Intron Sense
hsa-miR-29c 0.3 0.64 0.44 0.46  0.10 Intergenic
hsa-miR-29a 0.28 0.65 0.38 0.44  0.11 Intergenic
hsa-miR-30b 0.62 0.7 0.74 0.69  0.04 Intergenic
hsa-miR-30d 0.54 0.74 0.66 0.64  0.06 Intergenic
hsa-miR-130a 0.35 0.88 0.84 0.69  0.17 Intergenic
hsa-miR-210 0.76 0.57 0.31 0.54  0.13 Intergenic
hsa-miR-376a 0.11 0.1 0.22 0.14  0.04 Intergenic
hsa-miR-432 0.91 0.45 0.72 0.69  0.13 Intergenic
hsa-miR-125a hsa-miR-125a-5p 0.64 0.89 0.92 0.82  0.09 Intergenic
hsa-miR-181d 0.74 0.52 0.89 0.72  0.11 Intergenic
hsa-miR-27a 0.28 0.4 0.75 0.48  0.14 Intergenic
hsa-miR-296 hsa-miR-296-5p 0.44 0.9 0.4 0.58  0.16 Intergenic
hsa-miR-206 0.8 0.63 0.34 0.59  0.13 Intergenic
hsa-miR-125b 0.42 0.84 0.86 0.71  0.14 Intergenic
hsa-miR-193a hsa-miR-193a-3p 0.68 0.74 0.78 0.73  0.03 Intergenic
*miRNA identiﬁcations are from http://microrna.sanger.ac.uk/.
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points, we decided to focus on two representative muscle-
speciﬁc miRNAs, miR-1 and miR-133a (19). Their down-
regulation by insulin was conﬁrmed by quantitative RT-
PCR in muscle samples from a larger group of 15 healthy
subjects (Fig. 3A). We also investigated miR-1 and miR-
133a regulations in an insulin-deﬁcient mice model ob-
tained by streptozotocin treatment (20). Compared with
control mice, STZ-induced diabetic mice showed in-
creased miR-1 and miR-133a levels (Fig. 3B), whereas
insulin treatment resulted in the decrease of both miRNAs
(Fig. 3B). These data supported the downregulation of
miR-1 and miR-133a expression by insulin, observed in
human skeletal muscle. However, glucose uptake by skel-
etal muscle is robustly increased during the hyperinsuline-
mic clamp, and STZ-induced diabetic mice are also
markedly hyperglycemic (20). To verify whether glucose, a
strong transcriptional regulator (14), played a role in the
observed effects of insulin on miRNA levels, we measured
miR-1 and miR-133a expression in the skeletal muscle of
seven healthy men during a 3-h hyperglycemic-euinsuline-
mic clamp, an experimental situation designed to distin-
guish between the transcriptional effects of glucose and
those of insulin (14). Figure 3A showed that hyperglyce-
mia alone, in absence of hyperinsulinemia, did not modify
miR-1 or miR-133a levels in human muscle.
Since miR-1 and miR-133a are derived from introns of
protein-coding transcripts (i.e., MIB1 and C20orf166), it
could be conceivable that the observed downregulation of
miR-1 and miR-133a by insulin might be a consequence of
the downregulation of their host genes. Figure 4 indicated
that two host genes were in fact upregulated during insulin
infusion with a signiﬁcant effect for MIB1 (P  0.05) in
muscle samples. Therefore, regulations of MIB1 and
C20orf166 in response to insulin were unlikely to explain
the decreased levels of miR-1 and miR-133a.
Another potent mechanism controlling miRNA expres-
sion is the editing of their precursors by adenosine deami-
nases acting on RNAs, which can inhibit their processing
and thus can decrease mature miRNA levels (21). This
mechanism has been well described for miR-376a (21) and
included in the list of 39 downregulated miRNAs by insulin
(Table 1). We therefore veriﬁed whether primary tran-
scripts of miR-1 and miR-133a were edited in response to
insulin by sequencing pri-miRNA-1-1, pri-miRNA-1-2, pri-
miRNA-133a-1, and pri-miRNA-133a-2 cDNAs in muscle
samples from three healthy subjects before and after
hyperinsulinemia. Sequences were identical before and
after insulin infusion (data not shown), indicating that the
decreased levels of mature miR-1 and miR-133a were not
related to RNA editing.
Decreased expressions of miR-1/miR-133a by insu-
lin are correlated with MEF2C downregulation and
require SREBP-1c. Previous studies have shown that the
bicistronic transcript miR-1/miR-133a is regulated by
MEF2C, myogenic differentiation 1 (MYOD1), and serum
response factor (SRF), which regulate the activity of
enhancers located either upstream of miR-1/133a locus
or between the miR-1 and miR-133a coding regions
(11,13,22). To determine whether these transcription fac-
tors could be involved in the action of insulin, we quanti-
ﬁed their expression in human muscle in response to
insulin. Results indicated that MEF2C mRNA level was
signiﬁcantly reduced after insulin infusion (P  0.05, n 
15) (Fig. 5A), whereas expressions of MYOD1 and SRF
were slightly increased or unchanged. Thus, one could
postulate that reduction of MEF2C expression could con-
tribute to the downregulation of miR-1 and miR-133a.
Recently, we have found that MEF2C was downregu-
lated by SREBP-1c (15), a key mediator of insulin tran-
scriptional action in human muscle (23,24). This
observation suggested that insulin could downregulate
MEF2C and subsequently miR-1 and miR-133a expres-
sions through activation of SREBP-1c. Figure 5B demon-
strated that overexpression of SREBP-1c in human
myotubes robustly downregulates MEF2C mRNA levels.
Furthermore, overexpression of SREBP-1c was also asso-
ciated with a signiﬁcant reduction of miR-1 and miR-133a
expressions in myotubes (Fig. 5C). To determine whether
this reduction was a consequence of the downregulation
of MEF2C, we performed chromatin immunoprecipitation
TABLE 2
Other miRNAs regulated in vivo by insulin in human skeletal muscle, during a 3-h hyperinsulinemic-euglycemic clamp not expressed
in human muscle cells
miRNA names
(miRBase version 10)* Subject 1 Subject 2 Subject 3 Means  SE Host genes Genome context
hsa-miR-200c 8.85 1.33 1.37 3.85  2.50 Intergenic
hsa-miR-517c 0.34 0.48 0.18 0.33  0.09 Intergenic
hsa-miR-518b 0.39 0.41 0.76 0.52  0.12 Intergenic
hsa-miR-518c 0.93 0.45 0.27 0.55  0.20 Intergenic
hsa-miR-96 15.01 15.47 25.83 18.77  3.53 Intergenic
hsa-miR-575 7.50 15.87 9.11 10.82  2.56 SCD5 Intron Sense
hsa-miR-646 3.00 3.67 2.82 3.16  0.26 Novel transcript Intron Sense
*miRNA identiﬁcations are from http://microrna.sanger.ac.uk/.
FIG. 2. Transcript levels of components of the miRNA biogenesis pathway
before and after insulin infusion in 15 healthy subjects, determined by
qRT-PCR. *P < 0.05 and **P < 0.01 vs. control, respectively.
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bined with PCR ampliﬁcation of the MEF2C-binding site in
the enhancer region located between pri-miRNA-1-2 and
pri-miRNA-133a-1 (22). Figure 5D shows that after 48 h of
SREBP-1c overexpression in muscle cells, it was not
possible to detect by PCR MEF2C binding on this en-
hancer. This result conﬁrmed that SREBP-1c mediated
miR-1 and miR-133a downregulation through the down-
regulation of MEF2C in muscle cells. Finally, to demon-
strate that downregulations of miR-1 and miR-133a by
insulin were mediated by SREBP-1c, we knocked down
SREBP-1 expression in human myotubes before stimula-
tion by insulin and quantiﬁed the expressions of miR-1 and
miR-133a. Figure 5E showed that downregulations of
miR-1 and miR-133a by insulin observed in muscle cells
transfected with green ﬂuorescent protein siRNA (control)
was not detectable in cells transfected with SREBP-1
siRNA, conﬁrming that insulin regulation of these two
miRNAs was mediated by SREBP-1.
To determine whether the mechanism involving SREBP-
1c/MEF2C in the regulation of miR-1/miR-133a expres-
sions could be generalized to the downregulatory effect of
insulin on the set of miRNAs observed in the muscle
of healthy individuals, we quantiﬁed the expression of ﬁve
of them in muscle cells overexpressing SREBP-1c. As
shown in the supplementary Fig. S4, miR-107 and miR-95
displayed increased expressions, which is the opposite of
the marked downregulation observed during the clamp.
These results indicated that other cellular pathways than
SREBP-1c/MEF2C are likely involved in the regulation of
some of the 39 miRNAs in response to insulin.
Regulations of miR-1 and miR-133a are altered in
skeletal muscle of type 2 diabetic patients. Because
impaired insulin stimulation of SREBP-1c has been con-
sistently observed in skeletal muscle of type 2 diabetic
patients (25,26), we suspected that regulations of miR-1
and miR-133a by insulin could be altered in the muscle of
these patients. Figure 6A showed that basal expressions of
miR-133a and miR-1 were not signiﬁcantly different in
skeletal muscle from healthy individuals and insulin-resis-
tant type 2 diabetic patients. However, the effect of insulin
FIG. 3. A: Regulation of miR-1 and miR-133a during a hyperinsulinemic-euglycemic clamp (HIEG, f) or during a hyperglycemic-euinsulinemic
clamp (HGEI, u) in human skeletal muscle. *P < 0.05 vs. before clamp. B: miR-1 and miR-133a expressions in skeletal muscle of control,
STZ-induced diabetic, and insulin-treated STZ mice. **P < 0.01 vs. control mice.
M
I
B
1
 
/
H
P
R
T
 
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
)
0
5
10
15
20
25
30
Before HIEG After HIEG
0
100
200
300
400
500
Before HIEG After HIEG
C
2
0
o
r
f
1
6
6
 
/
H
P
R
T
 
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
)
(fold change = 1.4)
*
(fold change = 1.25)
FIG. 4. Quantiﬁcation by qRT-PCR of miR-1 and miR-133a host genes,
MIB1 and C20orf166, during insulin infusion in skeletal muscle (n 
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response to insulin was completely abolished for miR-
133a, and the effect on miR-1 expression was markedly
reduced, showing only a modest decrease that did not
reach signiﬁcance (P  0.2) (Fig. 6A). Concomitantly, the
signiﬁcant reduction in MEF2C expression observed dur-
ing the clamp in insulin-sensitive individuals was not
found in type 2 diabetic patients (Fig. 6B).
Detection of miRNA signals within the set of genes
regulated by insulin in human skeletal muscle. Previ-
ous microarray analyses have shown that reduction of
transcript levels can be observed following miRNA trans-
fection (6,7,22,27). It has been demonstrated that insulin
affects the expression level of 1,000 genes in vivo in
human skeletal muscle (1,2). It was therefore important to
determine whether insulin-regulated miRNAs could con-
tribute to the network of gene expression induced by
insulin in skeletal muscle. To this aim, we ﬁrst analyzed by
cDNA microarrays the global changes in mRNA levels in
the muscle of six healthy middle-aged subjects (including
samples from the three subjects used for miRNA analysis)
in response to insulin. Then we analyzed the 3 UTR region
of the upregulated mRNAs, assuming that downregulated
miRNAs by insulin would have their target genes upregu-
lated during the clamp. Among 944 upregulated genes, 357
can be predicted as a target of at least one miRNA
downregulated by insulin (predictions using TargetScan
version 4.2) (28). Since we observed that several binding
sites for distinct miRNAs were present on the same
transcript, we analyzed more in detail the distribution of
the number of miRNA-binding sites in this set of genes.
Figure 7 showed that the proportions of genes upregulated
by insulin that can be a target of at least one (or more)
distinct miRNA downregulated by insulin were signiﬁ-
cantly greater than the proportions of upregulated genes
that were not targets. Moreover, these proportions in-
creased with the number of distinct miRNA-binding sites
in the 3 UTR (Fig. 7). This observation suggested that
single miRNA induces moderate changes in expression of
their targets in response to insulin, while combinations
of different miRNAs can work in concert to exert
signiﬁcant effects on gene expression. This result is in
agreement with a previous study (29) showing that the
number and arrangement of miRNA recognition sites
can inﬂuence the degree and speciﬁcity of miRNA-
mediated gene repression.
To further explore the role of miRNAs in the insulin
transcriptional network, we analyzed the functions of the
predicted target genes for 39 downregulated miRNAs by
using the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database (30). To take into account that miRNAs
act as negative regulators of gene expression also by
FIG. 5. A: mRNA levels of key transcription factors implicated in
miR-1 and miR-133a skeletal muscle–speciﬁc expressions, during
hyperinsulinemic-euglycemic clamp (n  15). B: Variations in
MEF2C expression in human myotubes during overexpression of
human SREBP-1c. **P < 0.01. C: Variations in miR-1 and miR-
133a expressions in human myotubes overexpressing human
SREBP-1c. *P < 0.05. D: Decrease of MEF2C binding on the
enhancer located between miR-1 and miR-133a coding regions on
chromosome 18 (22) after SREBP-1c overexpression (ad-SREBP-
1c) in C2C12 muscle cell line. Input DNA (sheared chromatin,
positive control), Mock, ChIP without antibody (control); IP-IgG,
ChIP with antibody against IgG (negative control); IP-MEF2C,
ChIP with antibody against MEF2C; ad-GFP, cells infected with
adenoviruses expressing GFP as control. E: Variations in miR-1
and miR-133a expressions in response to insulin, after siRNA-
mediated knockdown of SREBP-1 (siSREBP1) in human muscle
cells. siRNA-mediated knockdown of GFP (siGFP) was used as
control.
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targets including those that were not regulated at the
mRNA level. Among 11,863 genes expressed in human
skeletal muscle (see RESEARCH DESIGN AND METHODS), 4,481
were the target of at least one regulated miRNA. Among
4,481 potential target genes, 1,279 were recorded at least
in one KEGG pathway. Table 3 shows KEGG pathways
that are most signiﬁcant in terms of containing more genes
than expected (P  0.05). This analysis revealed that
several signaling pathways and ubiquitin-mediated prote-
olysis are the major pathways potentially affected by 39
insulin-regulated miRNAs.
DISCUSSION
miRNAs form a novel class of regulators that add a new
level of regulation and ﬁne-tuning in the control of gene
expression. They are important for a wide range of cellular
functions, and recent studies have provided evidence that
miRNAs affect critical pathways of metabolic control, such
as adipocyte and skeletal muscle differentiation, amino
acid metabolism, lipid homeostasis, and insulin secretion
from pancreatic -cells (9). However, factors that govern
miRNA synthesis and expression in response to changes in
the cellular environment are still largely unknown. In this
study, we demonstrate for the ﬁrst time that insulin, the
major hormone controlling whole-body energy homeosta-
sis and metabolism, is involved in the regulation of miRNA
expression in human skeletal muscle, providing evidence
that regulation of miRNA expressions is a novel pathway
of insulin action in vivo. The fact that this regulation is also
observed in the murine model and that most of the
regulated miRNAs are expressed in other insulin-sensitive
tissues suggests that insulin action on miRNAs is not
restricted to our experimental situation and occurs more
generally in other tissues. Interestingly, 12 of 39 insulin
downregulated miRNAs have been previously found dys-
regulated in primary muscular disorders (31) (i.e., miR-
133a, miR-181d, miR-423, miR-30c, miR-95, miR-30b/d,
miR-206, miR-30a-5p, miR-26a, and miR-29a/c), suggest-
ing an important role of these miRNAs in speciﬁc physio-
logical pathways in skeletal muscle.
Although hundreds of miRNAs have been cloned in
various species, molecular actors involved in pri-miRNA
transcription are largely unknown. Recently, it has been
demonstrated that hepatocyte nuclear factor-1	 induces
miR-194 expression during intestinal epithelial cell differ-
entiation (32), that p53 transactivates miR-34a in pancre-
atic cells (33), that high mobility group at-hook 1 (HMGA1)
downregulates ﬁve different miRNAs in mouse embryonic
ﬁbroblasts (34), and that two different MEF2-dependent
enhancers regulated miR-1 and miR-133a expressions
during muscle differentiation (11,13,22). One important
result of this study is the demonstration that SREBP-1c
and MEF2C contribute to insulin action, at least on miR-1
and miR-133a, which were studied as representative miR-
NAs. The transcription factor SREBP-1 is mainly involved
in cholesterol and fatty acid metabolism (35). Recently, we
have published a microarray analysis of human muscle
FIG. 6. Regulation of miR-1, miR-133a (A), and MEF2C (B) expression
during a 3-h hyperinsulinemic-euglycemic clamp (HIEG) in skeletal
muscle of healthy subjects (1) and type 2 diabetic patients (f). *P <
0.05 vs. before clamp.
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FIG. 7. Global analysis of the relationship between the fold changes of
genes upregulated by insulin and the number of distinct miRNA-
binding sites in their 3 UTR (predictions from TargetScan 4.2). Genes
upregulated by insulin were divided into different subgroups according
to the number of miRNA-binding sites in 3 UTR (i.e., 39 miRNAs
downregulated by insulin). In each subgroup, we counted the number
of upregulated genes to compute the proportion of such genes in the
subgroup (e.g., miRNA count  5, contains genes that are targeted by
ﬁve or more distinct miRNAs). Subgroups in which the proportion of
upregulated genes is signiﬁcantly higher than when not the target are
in black (adjusted P < 0.05) or in gray (adjusted P < 0.10). The
absence of signiﬁcant difference (white) is due to the small size of the
subgroup for miRNA count  9. The black curve was obtained from
simple moving average over three data points, and the black line
indicates the percentage of genes upregulated by insulin that are not
targeted by miRNAs (5%).
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dred potential new target genes of this transcription
factor, including MEF2C. Here, we found that both insulin
in vivo in skeletal muscle and SREBP-1c overexpression in
muscle cells induced the coordinated downregulation of
MEF2C, miR-1, and miR-133a expressions. Thus, these
data led us to propose the following mechanism (Fig. 8):
Insulin activates the translocation of the SREBP-1c active
TABLE 3
KEGG pathways potentially affected by the 39 insulin-regulated miRNAs during a 3-h hyperinsulinemic-euglycemic clamp in human
skeletal muscle
KEGG pathways
KEGG
annotations
Number of genes
annotated on
microarray
Number of targeted
gene (six or more
miRNAs)* P (Fisher test)†
Adjusted P
(Benjamini)
MAPK signaling pathway ko04010 352 42 0.000392 0.00503
VEGF signaling pathway ko04370 93 16 0.000527 0.00503
Calcium signaling pathway ko04020 187 26 0.000613 0.00503
Ubiquitin-mediated proteolysis ko04120 206 27 0.001161 0.007934
mTOR signaling pathway ko04150 90 13 0.009689 0.039725
Wnt signaling pathway ko04310 255 28 0.01207 0.044987
Jak-STAT signaling pathway ko04630 179 21 0.015888 0.054284
The 11,864 genes retrieved from microarray data analysis were classiﬁed into KEGG categories. We determined signiﬁcant associations
between the set of genes collectively targeted by the 39 insulin-downregulated miRNAs and speciﬁc KEGG pathways. *We considered genes
targeted by at least six different miRNAs, which corresponded to percentile 95th of the distribution of predicted miRNA target sites in 3 UTR,
for the 11,864 expressed in human muscle, when using TargetScan 4.2 (conserved site across human, mouse, rat, and dog). †Enrichment was
signiﬁcant for P  0.05.
FIG. 8. Proposed mechanism to explain the downregulation of miR-1 and miR-133a by insulin in human skeletal muscle. Insulin activates the
translocation of SREBP-1c (BHLH) active form from the endoplasmic reticulum (ER) to the nucleus and, concomittantly, induces SREPB-1c
expression via the phosphatidylinositol (PI) 3-kinase (PI3K) signaling pathway (36). SREBP-1c mediates MEF2C downregulation (15) through
a mechanism that remains to be determined. As a consequence of lower MEF2C binding on their enhancer region, the transcription of miR-1 and
miR-133a is reduced, leading to decreased levels of their mature forms in muscle, after insulin treatment. Altered activation of PI 3-kinase and
SREBP-1c may explain the defective regulation of miR-1 and miR-133a expression in response to insulin in muscle of type 2 diabetic patients (25).
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expression via the phosphoinositide 3-kinase signaling
pathway (36). Then SREBP-1c induces MEF2C downregu-
lation and reduction of its binding to the pri-miRNA-1-2
and pri-miRNA-133a-1 enhancer region. This leads to the
reduction of miR-1 and miR-133a transcription and thus
to the decreased levels of their mature forms. Testing
this mechanism on ﬁve other miRNAs than miR-1 and
miR-133a, we found that two of them (miR-107 and
miR-95) were actually upregulated in muscle cells overex-
pressing SREBP-1c. This observation strongly suggests
that other mechanisms than the pathway involving
SREBP-1c/MEF2C are likely involved in the effects of
insulin on miRNA levels. Particularly, we cannot rule out the
fact that the decrease in miRNA concentrations may reﬂect
possible regulations of the miRNA-processing machinery
mediated by the miRNAs themselves. The insulin-induced
decrease in miRNA levels should thus be followed by
increased levels of target mRNAs, including those coding
for the proteins involved in their processing. In addition,
regulation of miRNA level during clamp could also be the
results of changes in the protein level or activity of
components of the miRNA processing machinery. Unfor-
tunately, the small size of the muscle biopsies did not
allow us to obtain enough material to verify these hypoth-
eses in human samples. Further studies are now required
to identify these alternative mechanisms.
One important result, which also supports the above-
proposed mechanism of insulin action on miRNA expres-
sions, is the observation that miR-1/miR-133a regulations
are altered in the muscle of type 2 diabetic patients during
the hyperinsulinemic clamp. Defective regulation of gene
expressions in response to insulin in peripheral tissues of
insulin-resistant type 2 diabetic patients has been re-
ported, including a marked alteration in the induction of
SREBP-1c expression (25,26). The present study demon-
strates that one of the unexpected consequences of this
defect is a marked alteration in the regulation of speciﬁc
miRNAs. Therefore, our data could also support the impli-
cation of miRNAs in the pathophysiology of type 2 diabe-
tes and insulin resistance in humans. Interestingly, in a
murine model of diabetes, 15 miRNAs have been found
differentially expressed in skeletal muscle when compared
with control rats (37). Two of 15 are present in the list of
insulin-regulated miRNAs (Table 1). Furthermore, overex-
pression of miR-29 has been shown to reduce insulin
action on protein kinase B/AKT activation in adipocytes
(37). Interestingly, miR-29a and miR-29c are among the
most regulated miRNAs in response to insulin in our study.
Taken together, these data strongly suggest that some
miRNAs regulated by insulin might be implicated in insulin
resistance.
Bioinformatic analysis showed that target genes of 39
miRNAs downregulated by insulin are mainly involved in
signaling pathways and in ubiquitination-mediated prote-
olysis. Previous data (1) have suggested that the ubiquitin-
proteasome system is an important component of insulin
action. Regarding intracellular signaling pathways, our
observation conﬁrmed previous in silico studies indicating
that miRNAs signiﬁcantly target proteins involved in signal
transduction (38,39). In agreement, a role for speciﬁc
miRNAs has been described in the regulation of insulin
receptor substrate-1 (40) and phosphatase and tensin ho-
molog (41) proteins. Here, our data suggested that p85	
phosphoinositide 3-kinase, a key mediator of insulin signal-
ing is a potential target for six different miRNAs down-
regulated by insulin (i.e., miR-376a, miR-107, miR-30a-3p,
miR-30e-3p, miR-29a, and miR-29c) (supplementary Table
S5).
This study reveals the contribution of miRNAs in the
transcriptional action of insulin in human skeletal muscle.
Although further studies are now required to understand
the biological impact of miRNAs in insulin action, the
observed dysregulation in patients with type 2 diabetes
may open potential perspectives for the understanding
of insulin resistance and development of therapeutic
strategies.
ACKNOWLEDGMENTS
This work was supported by INRA and INSERM and a
grant from ALFEDIAM-Roche.
No potential conﬂicts of interest relevant to this article
were reported.
The authors acknowledge Je ´re ´my Besson for microar-
ray data analysis; Corine Picat, Annie Durand, and Chris-
tine Durand for cell culture; May Faraj from the Endocrine
Service of Montreal University Hospital; and Giampiero
Bricca (Lyon University) for helpful discussions.
REFERENCES
1. Rome S, Clement K, Rabasa-Lhoret R, Loizon E, Poitou C, Barsh GS, Riou
JP, Laville M, Vidal H. Microarray proﬁling of human skeletal muscle
reveals that insulin regulates approximately 800 genes during a hyperin-
sulinemic clamp. J Biol Chem 2003;278:18063–18068
2. Coletta DK, Balas B, Chavez AO, Baig M, Abdul-Ghani M, Kashyap SR, Folli
F, Tripathy D, Mandarino LJ, Cornell JE, Defronzo RA, Jenkinson CP.
Effect of acute physiological hyperinsulinemia on gene expression in
human skeletal muscle in vivo. Am J Physiol Endocrinol Metab 2008;294:
E910–E917
3. Liu J. Control of protein synthesis and mRNA degradation by microRNAs.
Curr Opin Cell Biol 2008;20:214–221
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 2004;116:281–297
5. Liu T, Papagiannakopoulos T, Puskar K, Qi S, Santiago F, Clay W, Lao K,
Lee Y, Nelson SF, Kornblum HI, Doyle F, Petzold L, Shraiman B, Kosik KS.
Detection of a microRNA signal in an in vivo expression set of mRNAs.
PLoS ONE 2007;2:e804
6. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel
DP, Linsley PS, Johnson JM. Microarray analysis shows that some micro-
RNAs downregulate large numbers of target mRNAs. Nature 2005;433:769–
773
7. Arora A, Simpson DA. Individual mRNA expression proﬁles reveal the
effects of speciﬁc microRNAs. Genome Biol 2008;9:R82
8. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often ﬂanked by
adenosines, indicates that thousands of human genes are microRNA
targets. Cell 2005;120:15–20
9. Krutzfeldt J, Stoffel M. MicroRNAs: a new class of regulatory genes
affecting metabolism. Cell Metab 2006;4:9–12
10. Liang Y, Ridzon D, Wong L, Chen C. Characterization of microRNA
expression proﬁles in normal human tissues. BMC Genomics 2007;8:166
11. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM,
Conlon FL, Wang DZ. The role of microRNA-1 and microRNA-133 in
skeletal muscle proliferation and differentiation. Nat Genet 2006;38:228–
233
12. Rao PK, Kumar RM, Farkhondeh M, Baskerville S, Lodish HF. Myogenic
factors that regulate expression of muscle-speciﬁc microRNAs. Proc Natl
Acad SciUSA2006;103:8721–8726
13. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-
speciﬁc microRNA that targets Hand2 during cardiogenesis. Nature 2005;436:
214–220
14. Meugnier E, Faraj M, Rome S, Beauregard G, Michaut A, Pelloux V,
Chiasson JL, Laville M, Clement K, Vidal H, Rabasa-Lhoret R. Acute
hyperglycemia induces a global downregulation of gene expression in
adipose tissue and skeletal muscle of healthy subjects. Diabetes 2007;56:
992–999
15. Rome S, Lecomte V, Meugnier E, Rieusset J, Debard C, Euthine V, Vidal H,
Lefai E. Microarrays analysis of SREBP-1a and SREBP-1c target genes
A. GRANJON AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 58, NOVEMBER 2009 2563identify new regulatory pathways in muscle. Physiol Genomics 2008;34:
327–337
16. Grifﬁths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for
microRNA genomics. Nucleic Acid Res 2008;36:D154–D158
17. Kim YK, Kim VN. Processing of intronic microRNAs. EMBO J 2007;26:775–
783
18. Zhou X, Ruan J, Wang G, Zhang W. Characterization and identiﬁcation of
microRNA core promoters in four model species. PLoS Comput Biol
2007;3:e37
19. Callis TE, Chen JF, Wang DZ. MicroRNAs in skeletal and cardiac muscle
development. DNA Cell Biol 2007;26:219–225
20. Bonnard C, Durand A, Peyrol S, Chanseaume E, Chauvin MA, Morio B,
Vidal H, Rieusset J. Mitochondrial dysfunction results from oxidative
stress in the skeletal muscle of diet-induced insulin-resistant mice. J Clin
Invest 2008;118:789–800
21. Kawahara Y, Zinshteyn B, Sethupathy P, Iizasa H, Hatzigeorgiou AG,
Nishikura K. Redirection of silencing targets by adenosine-to-inosine
editing of miRNAs. Science 2007;315:1137–1140
22. Liu N, Williams AH, Kim Y, McAnally J, Bezprozvannaya S, Sutherland LB,
Richardson JA, Bassel-Duby R, Olson EN. An intragenic MEF2-dependent
enhancer directs muscle-speciﬁc expression of microRNAs 1 and 133. Proc
Natl Acad SciUSA2007;104:20844–20849
23. Dif N, Euthine V, Gonnet E, Laville M, Vidal H, Lefai E. Insulin activates
human sterol-regulatory-element-binding protein-1c (SREBP-1c) promoter
through SRE motifs. Biochem J 2006;400:179–188
24. Edwards PA, Tabor D, Kast HR, Venkateswaran A. Regulation of gene
expression by SREBP and SCAP. Biochim Biophys Acta 2000;1529:103–113
25. Ducluzeau PH, Perretti N, Laville M, Andreelli F, Vega N, Riou JP, Vidal H.
Regulation by insulin of gene expression in human skeletal muscle and
adipose tissue: evidence for speciﬁc defects in type 2 diabetes. Diabetes
2001;50:1134–1142
26. Sewter C, Berger D, Considine RV, Medina G, Rochford J, Ciaraldi T, Henry
R, Dohm L, Flier JS, O’Rahilly S, Vidal-Puig AJ. Human obesity and type 2
diabetes are associated with alterations in SREBP1 isoform expression
that are reproduced ex vivo by tumor necrosis factor-	. Diabetes 2002;51:
1035–1041
27. Sood P, Krek A, Zavolan M, Macino G, Rajewsky N. Cell-type-speciﬁc
signatures of microRNAs on target mRNA expression. Proc Natl Acad Sci
U S A 2006;103:2746–2751
28. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of
mammalian microRNA targets. Cell 2003;115:787–798
29. Hon LS, Zhang Z. The roles of binding site arrangement and combinatorial
targeting in microRNA repression of gene expression. Genome Biol
2007;8:R166
30. Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, Katayama T,
Kawashima S, Okuda S, Tokimatsu T, Yamanishi Y. KEGG for linking
genomes to life and the environment. Nucleic Acids Res 2008;36:D480–
D484
31. Eisenberg I, Eran A, Nishino I, Moggio M, Lamperti C, Amato AA, Lidov
HG, Kang PB, North KN, Mitrani-Rosenbaum S, Flanigan KM, Neely LA,
Whitney D, Beggs AH, Kohane IS, Kunkel LM. Distinctive patterns of
microRNA expression in primary muscular disorders. Proc Natl Acad Sci
U S A 2007;104:17016–17021
32. Hino K, Tsuchiya K, Fukao T, Kiga K, Okamoto R, Kanai T, Watanabe M.
Inducible expression of microRNA-194 is regulated by HNF-1alpha during
intestinal epithelial cell differentiation. RNA 2008;14:1433–1442
33. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH,
Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA,
Maitra A, Mendell JT. Transactivation of miR-34a by p53 broadly inﬂuences
gene expression and promotes apoptosis. Mol Cell 2007;26:745–752
34. De Martino I, Visone R, Fedele M, Petrocca F, Palmieri D, J MH, Forzati F,
Croce CM, Fusco A. Regulation of microRNA expression by HMGA1
proteins. Oncogene 2009;28:1432–42
35. Osborne TF. Sterol regulatory element-binding proteins (SREBPs): key
regulators of nutritional homeostasis and insulin action. J Biol Chem
2000;275:32379–32382
36. Nadeau KJ, Leitner JW, Gurerich I, Draznin B. Insulin regulation of sterol
regulatory element-binding protein-1 expression in L-6 muscle cells and
3T3 L1 adipocytes. J Biol Chem 2004;279:34380–34387
37. He A, Zhu L, Gupta N, Chang Y, Fang F. Overexpression of micro
ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin
resistance in 3T3–L1 adipocytes. Mol Endocrinol 2007;21:2785–2794
38. Stark A, Brennecke J, Bushati N, Russell RB, Cohen SM. Animal micro-
RNAs confer robustness to gene expression and have a signiﬁcant impact
on 3UTR evolution. Cell 2005;123:1133–1146
39. Cui Q, Yu Z, Purisima EO, Wang E. Principles of microRNA regulation of
a human cellular signaling network. Mol Syst Biol 2006;2:46
40. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, Baserga R.
Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the
growth of colon cancer cells. J Biol Chem 2007;282:32582–32590
41. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T.
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in
human hepatocellular cancer. Gastroenterology 2007;133:647–658
INSULIN REGULATES microRNA IN SKELETAL MUSCLE
2564 DIABETES, VOL. 58, NOVEMBER 2009 diabetes.diabetesjournals.org